Reza Dana, MD
6
0
0
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
16.7%
1 terminated/withdrawn out of 6 trials
83.3%
-3.2% vs industry average
0%
0 trials in Phase 3/4
120%
6 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
Role: lead
Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
Role: lead
Topical IL-1-Ra for Treatment of Posterior Blepharitis
Role: lead
Treatment of Corneal Neovascularization With Topical Pazopanib
Role: lead
Topical IL-1-Ra for Treatment of Corneal Neovascularization
Role: lead
Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)
Role: lead
All 6 trials loaded